Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

European Bioinformatics Sector Expected to Surge

By BiotechDaily International staff writers
Posted on 01 Jun 2014
An intra-European purchase agreement will boost the bioinformatics field by combining an exhaustive genomics data base with a highly intuitive software suite.

Qiagen N.V. (Venlo, The Netherlands) will be expanding its industry-leading portfolio of bioinformatics solutions called "Ingenuity Knowledge Base" by incorporating the genomics analysis and sequencing data that comprises the Biobase (Wolfenbüttel, Germany) HGMD (Human Gene Mutation Database) and PGMD (PharmacoGenomic Mutation Database) databases.

HGMD provides comprehensive data on human inherited disease mutations. Widely used in human genetics research, diagnostics, and personal genomics, HGMD enables quick access to single mutation queries and advanced search applications. PGMD identifies all published gene variants that have been shown to affect drug response in patients, with multiple delivery models for accessing this data, including an intuitive exploratory interface and a data download for in-house analysis systems.

“The ability of next-generation sequencing (NGS) to rapidly deliver genomic insights is opening up new frontiers for clinical research and medicine, and Qiagen is strategically addressing customers’ needs to interpret the massive amounts of data generated by NGS. With HGMD and other content from Biobase, a respected organization with a dedicated team and robust line of unique databases and software, Qiagen is further extending its competitive advantage as the overall market leader for clinical interpretation of human sequencing data,” said Peer M. Schatz, CEO of Qiagen. “Already today, more than 15,000 users worldwide rely on Qiagen’s bioinformatics products for interpretation and have processed over a quarter of a million genome sequences. HGMD is a unique fit with our offering and will integrate well. We expect to drive additional adoption of this leading literature-based knowledge base used by clinical reference labs for annotating hereditary variants, as well as Biobase’ other solutions by having integrated them into interpretation solutions shared with our Ingenuity Knowledge Base, adding value for Qiagen and Biobase customers and accelerating our growth drivers in NGS and bioinformatics.”

When the acquisition has been completed, Biobase will be renamed Qiagen Wolfenbüttel.

Related Links:
Qiagen N.V.
Biobase



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.